Table 1.
Sociodemographic and Clinical Characteristics of the Study Sample
| Characteristic | Infliximab (n=30) | Placebo (n=30) |
|---|---|---|
| Age (yrs.) – mean (SD) | 42.5 (8.2) | 44.3 (9.4) |
| Sex (female) – no. (%) | 20 (66%) | 20 (66%) |
| Ethnic Origin - no. (%) | ||
| Caucasian | 23 (77%) | 23 (77%) |
| Black | 6 (20%) | 5 (17%) |
| Other | 1 (3%) | 2 (6%) |
| Education (Highest Degree) – no. (%) | ||
| Graduate Degree | 8 (27%) | 7 (23%) |
| College Graduate | 13 (43%) | 13 (43%) |
| Partial College | 8 (27%) | 9 (30%) |
| High School Graduate | 1 (3%) | 1 (3%) |
| Unemployed (looking for work or disabled) – no. (%) | 12 (41%)+ | 12 (40%) |
| Age of Onset of MDD (yrs.) – mean (SD) | 19.1 (8.3) | 18.9 (10.7) |
| Lifetime Episodes of MDD – no. (SD) | 8.7 (24.8) | 7.8 (24.8) |
| Duration of Current MDD Episode (mos.) – mean (SD) | 184.4 (148.8) | 238.7 (165.25) |
| Antidepressant Trials in Current Episode – no. (SD) | 4.6 (3.2) | 3.7 (2.1) |
| MGH-S score – mean (SD) | 7.73 (6.6) | 6.1 (3.5) |
| Family History of MDD – no. (%) | 27 (90%) | 23 (82%)+ |
| Mood-Relevant Psychotropic Medication – no. (%) | 16 (53%) | 21 (70%) |
| Co-Morbid Medical Illness – no. (%) | 13 (43%) | 19 (63%) |
| Bipolar Disorder – no. (%) | 3 (10%) | 6 (20%) |
| BMI (kg/m2) – mean (SD) | 31.2 (6.9) | 32.7 (8.0) |
| Baseline hs-CRP (mg/L) – mean (SD) | 6.34 (8.9) | 5.45 (8.2) |
| Baseline HAM-D 17 – mean (SD) | 24.1 (4.0) | 23.6 (3.8) |
| Baseline CGI – mean (SD) | 4.8 (0.59) | 4.8 (0.81) |
yrs-years; SD-standard deviation; no.-number; MDD-major depressive disorder; mos.-months; MGH-S-Massachusetts General Hospital staging method; BMI-body mass index; hs-CRP-high sensitivity c-reactive protein; HAM-D 17-17-item Hamilton Depression Rating Scale; CGI-Clinical Global Impression severity scale; +-data on one subject was missing